Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3

Leukemia and Lymphoma

Volumn 49, Issue 10, 2008, Pages 1945-1953

  Zhou, Ying ^a   Uddin, Shahab ^a   Zimmerman, Todd ^a   Kang, Jeong Ah ^a   Ulaszek, Jodie ^a   Wickrema, Amittha ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Apoptosis; Glycogen synthase kinase 3; Myeloma

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FAS LIGAND; FORKHEAD TRANSCRIPTION FACTOR; GLYCOGEN SYNTHASE KINASE 3; I KAPPA B ALPHA; TRANSCRIPTION FACTOR FKHRL1;

APOPTOSIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL ISOLATION; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FAS LIGAND PROTEIN; FORKHEAD TRANSCRIPTION FACTORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; I-KAPPA B PROTEINS; MULTIPLE MYELOMA; PROTEIN KINASE INHIBITORS; THIADIAZOLES;

EID: 55049086241     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802304966     Document Type: Conference Paper

References (44)

1. Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G. and Anderson, K. C. (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer, 7, pp. 585-598.
2. Xu, F. H., Sharma, S., Gardner, A., Tu, Y., Raitano, A., Sawyers, C. and Lichtenstein, A. (1998) Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: Support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood, 92, pp. 241-251.
3. Puthier, D., Bataille, R. and Amiot, M. (1999) IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol, 29, pp. 3945-3950.
4. Ge, N. L. and Rudikoff, S. (2000) Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood, 96, pp. 2856-2861.
5. Stromberg, T., Ekman, S., Girnita, L., Dimberg, L. Y., Larsson, O. Axelson, M. et al. (2006) IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood, 107, pp. 669-678.
6. Tu, Y., Gardner, A. and Lichtenstein, A. (2000) The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: Roles in cytokine-dependent survival and proliferative responses. Cancer Res, 60, pp. 6763-6770.
7. Mitsiades, C. S., Mitsiades, N., Poulaki, V., Schlossman, R., Akiyama, M. Chauhan, D. et al. (2002) Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications. Oncogene, 21, pp. 5673-5683.
8. Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P. and Anderson, K. C. (2001) The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene, 20, pp. 4519-4527.
9. Ghosh, J. C. and Altieri, D. C. (2005) Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells. Clin Cancer Res, 11, pp. 4580-4588.
10. Ougolkov, A. V. and Billadeau, D. D. (2006) Targeting GSK-3: A promising approach for cancer therapy?. Future Oncol, 2, pp. 91-100.
11. Tsuchiya, K., Nakamura, T., Okamoto, R., Kanai, T. and Watanabe, M. (2007) Reciprocal targeting of Hath1 and beta-catenin by Wnt glycogen synthase kinase 3β in human colon cancer. Gastroenterology, 132, pp. 208-220.
12. Cohen, P. and Frame, S. (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol, 2, pp. 769-776.
13. Doble, B. W. and Woodgett, J. R. (2003) GSK-3: Tricks of the trade for a multi-tasking kinase. J Cell Sci, 116, pp. 1175-1186.
14. Frame, S. and Cohen, P. (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem J, 359, pp. 1-16.
15. Shaw, M. and Cohen, P. (1999) Role of protein kinase B and the MAP kinase cascade in mediating the EGF-dependent inhibition of glycogen synthase kinase 3 in Swiss 3T3 cells. FEBS Lett, 461, pp. 120-124.
16. Armstrong, J. L., Bonavaud, S. M., Toole, B. J. and Yeaman, S. J. (2001) Regulation of glycogen synthesis by amino acids in cultured human muscle cells. J Biol Chem, 276, pp. 952-956.
17. Birkenkamp, K. U. and Coffer, P. J. (2003) Regulation of cell survival and proliferation by the FOXO (Forkhead box, class O) subfamily of Forkhead transcription factors. Biochem Soc Trans, 31, pp. 292-297.
18. Dijkers, P. F., Medema, R. H., Pals, C., Banerji, L., Thomas, N. S. Lam, E. W. et al. (2000) Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol, 20, pp. 9138-9148.
19. Kops, G. J., Medema, R. H., Glassford, J., Essers, M. A., Dijkers, P. F., Coffer, P. J., Lam, E. W. and Burgering, B. M. (2002) Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol, 22, pp. 2025-2036.
20. Burgering, B. M. and Medema, R. H. (2003) Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol, 73, pp. 689-701.
21. Van Der Heide, L. P., Hoekman, M. F. and Smidt, M. P. (2004) The ins and outs of FoxO shuttling: Mechanisms of FoxO translocation and transcriptional regulation. Biochem J, 380, pp. 297-309.
22. Martinez, A., Alonso, M., Castro, A., Perez, C. and Moreno, F. J. (2002) First non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem, 45, pp. 1292-1299.
23. Wickrema, A., Uddin, S., Sharma, A., Chen, F., Alsayed, Y. Ahmad, S. et al. (1999) Engagement of Gab1 and Gab2 in erythropoietin signaling. J Biol Chem, 274, pp. 24469-24474.
24. Falschlehner, C., Emmerich, C. H., Gerlach, B. and Walczak, H. (2007) TRAIL signalling: Decisions between life and death. Int J Biochem Cell Biol, 39, pp. 1462-1475.
25. Hideshima, T., Nakamura, N., Chauhan, D. and Anderson, K. C. (2001) Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene, 20, pp. 5991-6000.
26. Maaza, G-A, Uddin, S., Mahmud, D., Damacela, I., Lavelle, D. Ahmed, M. et al. (2002) Regulation of myeloma cell growth through Akt/Gsk3/ forkhead signaling pathway. Biochem Biophys Res Commun, 297, pp. 760-764.
27. Reagan-Shaw, S. and Ahmad, N. (2007) The role of Forkhead-box Class O (FoxO) transcription factors in cancer: A target for the management of cancer. Toxicol Appl Pharmacol, 224, pp. 360-368.
28. Hideshima, T., Neri, P., Tassone, P., Yasui, H., Ishitsuka, K. Raje, N. et al. (2006) MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res, 12, pp. 5887-5894.
29. Frelin, C., Imbert, V., Griessinger, E., Loubat, A., Dreano, M. and Peyron, J. F. (2003) AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells. Oncogene, 22, pp. 8187-8194.
30. Ni, H., Ergin, M., Huang, Q., Qin, J. Z., Amin, H. M. Martinez, R. L. et al. (2001) Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: Downregulation of NF-kappa B induces apoptosis. Br J Haematol, 115, pp. 279-286.
31. Bjorkstrand, B. and Gahrton, G. (2007) High-dose treatment with autologous stem cell transplantation in multiple myeloma: Past, present, and future. Semin Hematol, 44, pp. 227-233.
32. Vescio, R. A., Han, E. J., Schiller, G. J., Lee, J. C., Wu, C. H. Cao, J. et al. (1996) Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant, 18, pp. 103-110.
33. Vogel, W., Kopp, H. G., Kanz, L. and Einsele, H. (2005) Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol, 131, pp. 214-218.
34. Gazitt, Y., Reading, C. C., Hoffman, R., Wickrema, A., Vesole, D. H. Jagannath, S. et al. (1995) Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells. Blood, 86, pp. 381-389.
35. Trowbridge, J. J., Xenocostas, A., Moon, R. T. and Bhatia, M. (2006) Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat Med, 12, pp. 89-98.
36. Bug, G., Gul, H., Schwarz, K., Pfeifer, H., Kampfmann, M. Zheng, X. et al. (2005) Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res, 65, pp. 2537-2541.
37. Goldman-Leikin, R. E., Salwen, H. R., Herst, C. V., Variakojis, D., Bian, M. L. Le Beau, M M et al. (1989) Characterization of a novel myeloma cell line, MM.1. J Lab Clin Med, 113, pp. 335-345.
38. Moalli, P. A., Pillay, S., Weiner, D., Leikin, R. and Rosen, S. T. (1992) A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood, 79, pp. 213-222.
39. Gazdar, A. F., Oie, H. K., Kirsch, I. R. and Hollis, G. F. (1986) Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood, 67, pp. 1542-1549.
40. Matsuoka, Y., Moore, G. E., Yagi, Y. and Pressman, D. (1967) Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med, 125, pp. 1246-1250.
41. Nilsson, K. (1971) Synthesis and secretion of IgE by an established human myeloma cell line. Clin Exp Immunol, 9, pp. 785-793.
42. Nilsson, K., Bennich, H., Johansson, S. G. and Ponten, J. (1970) Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol, 7, pp. 477-489.
43. Dalton, W. S., Durie, B. G., Alberts, D. S., Gerlach, J. H. and Cress, A. E. (1986) Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res, 46, pp. 5125-5130.
44. Dalton, W. S., Grogan, T. M., Meltzer, P. S., Scheper, R. J., Durie, B. G. Taylor, C. W. et al. (1989) Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol, 7, pp. 415-424.